Clinical trials / NCT03834753
NCT03834753Phase 3Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Study sponsor: Outlook Therapeutics, Inc. · OTLK

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2021-06-07Actual
Enrollment · participants228Actual
Source updated2026-08-03Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Proportion of subjects who gain 15 or more letters in best corrected visual acuity (BCVA)

+ After

Measure: Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)

Check registry source